Itolerance,

Biotechnology Research · 2 Employees
Email Address: itolerance@jtcir.com
  • Overview
  • Employees
Access 8 Verified Employees Profiles for Itolerance,Unlock Free Contacts Now
About
iTolerance is a privately held regenerative medicine company enabling tissue, organoid or cell therapy without the need for life-long immunosuppression. Leveraging our proprietary technology platform, iTOL-100, we are advancing a pipeline of programs using both allogenic pancreatic islets and stem-cells that have the potential to cure diseases. Our lead program, iTOL-101 is being developed for Type 1 Diabetes and in a preclinical non-human primate study, pancreatic islet cells co-implanted with iTOL-101 exhibited long-term function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression. Our follow-on candidate, iTOL-102 is leveraging significant advancements in stem cells, which allows a potentially inexhaustible supply of insulin-producing cells for use in Type 1 Diabetes. Additionally, the Company is developing iTOL-201 for liver failure and iTOL-301 as a potential regenerative protein and cell therapy that leverages stem cell sources to produce proteins or hormones in the body in conditions of high unmet need.
Year Founded
2020
Social Media
Linkedin
Industry
Biotechnology Research
HQ Location
Miami, FL 33136, US
Keywords
--
Location
  • Miami, FL 33136, US

Email Formats

Sign up for free credits and discover verified email addresses of Itolerance,
FormatExamples
first + last
andywarhol@itolerance.com
first_initial + last
awarhol@itolerance.com
first + last_initial
andyw@itolerance.com
first
andy@itolerance.com
last
warhol@itolerance.com
Get Verified Emails for 8 Itolerance, Employees

Frequently Asked Questions

Learn More about Itolerance,

Similar Companies

Biotechnology Research

Get key business info for Itolerance, and other 100M companies. Start your seach.

No Credit Card Needed. By signing up, you understand and agree to Futern's Terms and Policy.